HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.

AbstractBACKGROUND:
To determine the efficacy of pegylated interferon-α (PEG-IFN-α) therapy for 24 months in chronic delta hepatitis (CDH).
METHODS:
Patients with CDH who were treated by PEG-IFN-α2a or -2b for 24 months were included in the study. Demographic, biochemical and virological parameters were recorded at baseline and during follow-up. All included patients completed a treatment period of 24 months and at least a 6 month (range 6-60) follow-up period. Biochemical and virological response rates at end of treatment and end of follow-up were calculated, and predictors of sustained virological response (SVR) were analysed.
RESULTS:
In total, 32 patients (22 males; mean age ± SD 42.7 ± 12 years) with CDH who were treated with PEG-IFN-α2a (180 µg) or -2b (1.5 µg/kg) once a week subcutaneously for 24 months were included in the study. All patients had compensated liver disease (25 [78%] were non-cirrhotic), increased transaminase levels and HDV RNA positivity at baseline. Genotypic analyses of HDV showed genotype I in all. Mean duration of follow-up was 19.5 months. At the end of treatment, virological response was achieved in 16 (50%) patients. SVR at the end of follow-up was achieved in 15 (47%) patients. A negative HDV RNA at 6 months of treatment was the only predictor of SVR (OR = 20; 95% CI 2, 195; P = 0.01).
CONCLUSIONS:
PEG-IFN-α treatment achieved SVR in approximately half of the patients with CDH, and relapse rate was very low during the follow-up. Negativity of HDV RNA at 6 months may predict SVR in CDH.
AuthorsCetin Karaca, Ozlem M Soyer, Bulent Baran, Asli C Ormeci, Suut Gokturk, Esra Aydin, Sami Evirgen, Filiz Akyuz, Kadir Demir, Fatih Besisik, Sabahattin Kaymakoglu
JournalAntiviral therapy (Antivir Ther) Vol. 18 Issue 4 Pg. 561-6 ( 2013) ISSN: 2040-2058 [Electronic] England
PMID22976528 (Publication Type: Journal Article)
Chemical References
  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2b
  • peginterferon alfa-2a
Topics
  • Adolescent
  • Adult
  • Antiviral Agents (therapeutic use)
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Hepatitis D, Chronic (blood, diagnosis, drug therapy, virology)
  • Hepatitis Delta Virus (drug effects, physiology)
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (therapeutic use)
  • Male
  • Middle Aged
  • Molecular Typing
  • Polyethylene Glycols (therapeutic use)
  • Prognosis
  • RNA, Viral (antagonists & inhibitors, blood)
  • Recombinant Proteins (therapeutic use)
  • Treatment Outcome
  • Viral Load (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: